Name:
COVID AND Anticoagulants
Description:
COVID AND Anticoagulants
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/83725d5d-bc1a-446b-824d-691ea2058a77/thumbnails/83725d5d-bc1a-446b-824d-691ea2058a77.jpeg?sv=2019-02-02&sr=c&sig=M0KlfrcPhutY4EKKyN7wHyxpkZcXDtYPsz5U8rcWpEE%3D&st=2024-12-22T06%3A24%3A53Z&se=2024-12-22T10%3A29%3A53Z&sp=r
Duration:
T00H03M15S
Embed URL:
https://stream.cadmore.media/player/83725d5d-bc1a-446b-824d-691ea2058a77
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/83725d5d-bc1a-446b-824d-691ea2058a77/18777435.mp3?sv=2019-02-02&sr=c&sig=d9PNF0TTg0ezDNj2OJ5Tzi4UKnyrnQgodjWL3h3a97k%3D&st=2024-12-22T06%3A24%3A53Z&se=2024-12-22T08%3A29%3A53Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst The Heart Board Review, and other online resources available only through accesscardiology.com. [ Music ] >> It's become quite obvious that COVID-19 is associated with several non-pulmonary complications. I guess the issue is what do we know about the other clinical effects of COVID-19? [ Music ] Hi, Dr. Bernie here, and welcome to Practice Impact Extra.
Critical care physicians and cardiologists caring for COVID-D hospitalized patient began noting large numbers of patients with high levels of blood clotting, leading to the potentially deadly thromboembolic events that have been noted. In light of this, I want to share a study published in JACC, the Journal American College of Cardiology, in May of 2020. That's the report and the results of anti-coagulation and survival in COVID-D hospitalized patients. A team of researchers at Mount Sinai Hospital in New York City evaluated 2,773 records of confirmed COVID-D patients between March 14 and April 11.
Of the 2,773 hospitalized COVID-positive patients, 786, 28%, received systemic anti-coagulation during the hospital stay. They measured two outcomes, including the survival of those on anti-coagulation and those not on blood thinners and also bleeding rate. So what was the result? The median survival increased from 14 days to 21 days with the addition of anticoagulation.
Very interesting. Amongst sicker patients who required mechanical ventilation, the in-hospital mortality fell from 62% to 29%, a very significant decline. And the median survival jumped from 9 days to 21 days. As it related to bleeding, there was no increased bleeding, with 3% in the anti-coagulated group and 1.9% in the placebo group that did not receive any anti-coagulant.
So what's my thinking? Eh, this is really a preliminary report. However, I believe anti-coagulation should be considered when patients are hospitalized for COVID-19 to possibly improve outcome. I would stress that a personalized individual medical decision is necessary for every COVID-D patient to assess for the risk of bleeding. Thank you again for joining me, and see you next time on Practice Impact Extra.
>> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to AccessCardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features. To subscribe or learn more, please visit accesscardiology.com.
